^
Association details:
| Biomarker: | ITGB6 expression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | sigvotatug vedotin (PF-08046047) (Microtubule inhibitor, Integrin beta-6 -targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Published date:
08/25/2023
Excerpt:
The antibody component of SGN-B6A is specific for integrin beta-6 and does not bind other alpha-v family members. In preclinical studies, this ADC has demonstrated activity in vivo in models derived from non-small cell lung, pancreatic, pharyngeal, and bladder carcinomas spanning a range of antigen expression levels.
DOI:
10.1158/1535-7163.MCT-22-0817
